Skip to main content

Crohn's & Colitis
blogs, news & research

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

By Shomron Ben-Horin, Miri Yavzori, Itai Benhar, Ella Fudim, Orit Picard, Bella Ungar, SooYoung Lee, SungHwan Kim, Rami Eliakim, Yehuda Chowers

Scientists conducted a study on 125 patients to test the cross-immunogenicity of the approved infliximab-biosimilar Remsima (CT-P13) with the originator drug Remicade. They found that Anti-Remicade antibodies within patients with IBD had the effect of functionally inhabiting Remsima to a similar degree. This is suggestive of common immunogenicity and shared immunodominant epitopes on these two infliximab agents. When compared with anti-adalimumab antibodies scientists noted no cross-reaction with Remsima or Remicade.

Crohn’s and Colitis Australia would like to thank BMJ Journals for permission to use this article.



Posted on: February 23 2018

Leave a comment

Your email address will not be published. Required fields are marked *

Good article. I certainly appreciate this site. Continue the good work!

I was very interested in the article "Good Vs bad bacteria - the bugs responsible for Crohn's disease". I was diagnosed with IBD 6 months ago and after a very bad reaction to Pentasa (but unproven) I was told to wait and try again when the symptoms peaked again. However, I started taking Probiotics each day and (touch wood) I have been in remission for 5 months, with high hopes. I am very interested in the research in this field.

My 16 year old daughter was diagnosed with UC in July 2016 and after 4 flare ups within 12 months and trying different medications, she was prescribed infliximab. This has been the miracle medication for her and am so thankful that she has been able to return to a "relatively normal life", enjoying school and her passion for sports again (bar 8 weekly visits to PMH for inflixmab infusions, routine colonoscopies and mezzaline daily). I had very little knowledge of UC and autoimmunie disease for that matter; and was shellshocked at how debilitating it can be. We are so grateful to have a wonderful gastro and medical team supporting my daughter and of course the impact that inflixmab has had; however know it is still early days and don't want to take anything for granted.

About the author

Crohns & Colitis